Black Diamond Therapeutics
Stock Forecast, Prediction & Price Target
Black Diamond Therapeutics Financial Estimates
Black Diamond Therapeutics Revenue Estimates
Black Diamond Therapeutics EBITDA Estimates
Black Diamond Therapeutics Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $438K Low: $438K High: $438K avg. 0% | Avg: $3.89M Low: $3.89M High: $3.89M avg. 788.81% | Avg: $12.91M Low: $12.91M High: $12.91M avg. 231.74% | Avg: $160.38M Low: $160.38M High: $160.38M avg. 1141.83% |
Net Income
% change YoY
| $-123.20M N/A | $-84.52M 31.39% | $-82.44M 2.45% | Avg: $-109.86M Low: $-94.94M High: $-55.82M avg. -33.26% | Avg: $-135.44M Low: $-99.77M High: $-50.54M avg. -23.28% | Avg: $-98.23M Low: $-98.23M High: $-98.23M avg. 27.46% | Avg: $-50.54M Low: $-50.54M High: $-50.54M avg. 48.54% |
EBITDA
% change YoY
| $-125.59M N/A | $-95.06M 24.31% | $-86.02M 9.50% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$3.4 N/A | -$2.33 31.47% | -$1.88 19.31% | Avg: -$1.67 Low: -$2.16 High: -$1.27 avg. 11.17% | Avg: -$1.77 Low: -$2.27 High: -$1.15 avg. -6.10% | Avg: -$2.24 Low: -$2.24 High: -$2.24 avg. -26.12% | Avg: -$1.15 Low: -$1.15 High: -$1.15 avg. 48.54% |
Operating Expenses
% change YoY
| $126.87M N/A | $92.82M -26.83% | $86.46M -6.85% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Black Diamond Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 4.86% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -94.94M, average is -109.86M and high is -55.82M.
What is Black Diamond Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 540.59% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $438K, average is $438K and high is $438K.
What is Black Diamond Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 6.86% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$2.16, average is -$1.67 and high is $-1.27.
What is the best performing analyst?
In the last twelve months analysts have been covering Black Diamond Therapeutics stock. The most successful analyst is Joseph Calanzaro.